Patents by Inventor Eugene J. Segre

Eugene J. Segre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating diseases by daily administration of 6-chloro-11.beta.,17.alpha.,21-trihydroxypregna-1,4,6-triene-3,20-dione
    Patent number: 4051241
    Abstract: This invention relates to a method of treating allergic, dermatologic and rheumatic diseases in mammals which comprises daily orally administering to said mammal in a single dose an effective amount of 6-chloro-11.beta.,17.alpha.,21-trihydroxypregna-1,4,6-triene-3,20-dione.
    Type: Grant
    Filed: August 12, 1976
    Date of Patent: September 27, 1977
    Assignee: Syntex (U.S.A.) Inc.
    Inventor: Eugene J. Segre
  • Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
    Patent number: 3942641
    Abstract: This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.
    Type: Grant
    Filed: March 24, 1975
    Date of Patent: March 9, 1976
    Assignee: Syntex Corporation
    Inventor: Eugene J. Segre
  • Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
    Patent number: 3932635
    Abstract: This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.
    Type: Grant
    Filed: May 5, 1972
    Date of Patent: January 13, 1976
    Assignee: Syntex Corporation
    Inventor: Eugene J. Segre